EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieMultizentrische Studie

Factors Influencing Nerinetide Effect on Infarct Volume in Patients Without Alteplase in the Randomized ESCAPE-NA1 Trial

Johanna M Ospel iD, Mayank Goyal iD, Bijoy K Menon iD, Mohammed A Almekhlafi iD, Charlotte Zerna iD, Raul G Nogueira iD, Ryan A McTaggart iD, Andrew M Demchuk iD, Alexandre Y Poppe iD, Jeremy L Rempel iD, Manish Joshi iD, Nima Kashani iD and 14 more

Stroke · 2025-01 · 56 (1) · 14-21

DOI: 10.1161/strokeaha.124.048601 ↗

At a glance

Randomisierte kontrollierte Studie in Stroke, 2025-01. Written by Johanna M Ospel and 25 co-authors. Institution: Department of Diagnostic Imaging (J.M.O., M.G., B.K.M., M.A.A., A.M.D., M.J., M.D.H.), University of Calgary, Alberta, Canada. Major MEDLINE topics: Tissue Plasminogen Activator, Ischemic Stroke. Cited 8 times so far (Crossref); 29 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

BACKGROUND: In the ESCAPE-NA1 trial (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischemic Stroke), treatment with nerinetide was associated with a smaller infarct volume among patients who did not receive intravenous alteplase. We assessed the effect of nerinetide on the surrogate imaging outcome of final infarct volume in patients who did not receive intravenous alteplase and explored predictors of outcome and modifiers of nerinetide’s effect on infarct volume. METHODS: ESCAPE-NA1 was a multicenter, randomized trial in which patients with acute stroke with a baseline Alberta Stroke Program Early CT Score >4, undergoing endovascular thrombectomy, were randomized to receive intravenous nerinetide or placebo. Patients not receiving intravenous alteplase were included in this post hoc secondary analysis of the trial data. Final infarct volume was manually segmented on 24-hour noncontrast computed tomography or diffusion-weighted magnetic resonance imaging. Predictors of final infarct volume were identified using multivariable linear regression with cubic-root-transformed infarct volume as the dependent variable. Evidence of treatment-by-predictor interaction was tested by including interaction terms in the model. RESULTS: Four hundred forty-six patients (219 who received nerinetide and 227 who received a placebo) out of a total of 1105 enrolled patients were included in this secondary post hoc analysis of the randomized ESCAPE-NA1 trial. Nerinetide was a strong predictor of smaller infarct volume (adjusted β coefficient, −0.35 [95% CI, −0.67 to −0.02]). Other predictors of smaller infarct volume were history of hypertension, good pial collateral filling on multiphase computed tomography angiography, a middle cerebral artery occlusion compared with an internal carotid artery occlusion, lower baseline National Institutes of Health Stroke Scale score, lower baseline systolic blood pressure, lower baseline serum glucose, shorter onset-to-randomization time, and higher Alberta Stroke Program Early CT Score. There was evidence of a treatment-by-systolic blood pressure and treatment-by-anesthesia interaction: nerinetide attenuated the negative effects of elevated baseline ( P interaction =0.02) and postdose ( P interaction =0.04) systolic blood pressure and use of general anesthesia ( P interaction =0.06) on final infarct volume. We observed a marginally significant interaction with reperfusion status, such that nerinetide may attenuate the harmful effect of poor reperfusion status on infarct volume ( P interaction =0.08). CONCLUSIONS: Nerinetide treatment was strongly associated with smaller final infarct volumes among patients not cotreated with alteplase. The reduction in infarct volume was greater among patients with poor prognostic factors. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02930018.

Subjects

MeSH terms (MEDLINE)

Tissue Plasminogen ActivatorIschemic StrokeHumansFemaleMaleAgedMiddle AgedAged, 80 and overFibrinolytic AgentsTreatment OutcomeDiffusion Magnetic Resonance ImagingThrombectomyDouble-Blind Method

Author keywords

blood pressureglucosehumansinfarctionstroke

Substances

Tissue Plasminogen ActivatorFibrinolytic Agents

Authors and institutions

  • Department of Diagnostic Imaging (J.M.O., M.G., B.K.M., M.A.A., A.M.D., M.J., M.D.H.), University of Calgary, Alberta, Canada.
  • Department of Clinical Neurosciences (J.M.O., M.G., B.K.M., M.A.A., A.M.D., M.D.H.), University of Calgary, Alberta, Canada.
  • Staedtisches Klinikum Dresden, Germany (C.Z.).
  • Department of Neurology, University of Pittsburgh Medical Centre, KS (R.G.N.).
  • Department of Interventional Radiology, Warren Alpert Medical School of Brown University, Providence, RI (R.A.M.).
  • Division of Neurology, Centre Hospitalier de l'Université de Montréal, Quebec, Canada (A.Y.P.).

ORCID profiles: Johanna M Ospel, Mayank Goyal, Bijoy K Menon, Mohammed A Almekhlafi, Charlotte Zerna, Raul G Nogueira, Ryan A McTaggart, Andrew M Demchuk, Alexandre Y Poppe, Jeremy L Rempel, Manish Joshi, Nima Kashani, Thalia S Field, Darius Dowlatshahi, Brian van Adel, Richard H Swartz, Eric Sauvageau, Volker Puetz, Frank L Silver, Bruce Campbell, René Chapot, Michael Tymianski, Michael D Hill

Cite

APA

Ospel, J. M., Goyal, M., Menon, B. K., Almekhlafi, M. A., Zerna, C., Nogueira, R. G., McTaggart, R. A., Demchuk, A. M., Poppe, A. Y., Rempel, J. L., Joshi, M., Kashani, N., Heard, K., Field, T. S., Dowlatshahi, D., van Adel, B., Swartz, R. H., Shah, R., Sauvageau, E., …, & ESCAPE-NA1 Investigators (2025). Factors Influencing Nerinetide Effect on Infarct Volume in Patients Without Alteplase in the Randomized ESCAPE-NA1 Trial. Stroke, 56(1), 14-21. https://doi.org/10.1161/strokeaha.124.048601

Vancouver

Ospel JM, Goyal M, Menon BK, Almekhlafi MA, Zerna C, Nogueira RG, et al. Factors Influencing Nerinetide Effect on Infarct Volume in Patients Without Alteplase in the Randomized ESCAPE-NA1 Trial. Stroke. 2025;56(1):14-21. doi:10.1161/strokeaha.124.048601

BibTeX
@article{Ospel2025,
  author = {Ospel, Johanna M and Goyal, Mayank and Menon, Bijoy K and Almekhlafi, Mohammed A and Zerna, Charlotte and Nogueira, Raul G and McTaggart, Ryan A and Demchuk, Andrew M and Poppe, Alexandre Y and Rempel, Jeremy L and Joshi, Manish and Kashani, Nima and Heard, Kathy and Field, Thalia S and Dowlatshahi, Darius and van Adel, Brian and Swartz, Richard H and Shah, Ruchir and Sauvageau, Eric and Puetz, Volker and Silver, Frank L and Campbell, Bruce and Chapot, René and Tymianski, Michael and Hill, Michael D and ESCAPE-NA1 Investigators, ESCAPE-NA1 Investigators},
  title = {Factors Influencing Nerinetide Effect on Infarct Volume in Patients Without Alteplase in the Randomized ESCAPE-NA1 Trial},
  journal = {Stroke},
  year = {2025},
  volume = {56},
  number = {1},
  pages = {14--21},
  doi = {10.1161/strokeaha.124.048601}
}
Start for free →